Jeffrey Yu - 17 Jun 2025 Form 4 Insider Report for OneMedNet Corp (ONMD)

Reporting relationship: Chief Medical Officer, Director
Issuer ticker: ONMD
Reported as of: 17 Jun 2025
Net transaction value: +$2,257,842
SEC form: 4
Accepted by SEC: 26 Nov 2025, 21:56:08 UTC
Prior SEC filing: 26 Nov 2025
Next SEC filing: 24 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Golden, Attorney-in-Fact

Key filing fact

Jeffrey Yu filed Form 4 for OneMedNet Corp (ONMD) on 26 Nov 2025.

Key facts

This page summarizes Jeffrey Yu's Form 4 filing for OneMedNet Corp (ONMD).
24 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 26 Nov 2025, 21:56.

Change

Previous filing in this sequence was filed on 26 Nov 2025.
Current net transaction value: +$2,257,842.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001991132 Primary reporting owner

Yu Jeffrey

Relationship: Chief Medical Officer, Director
Address: 6385 OLD SHADY OAK ROAD, SUITE 250, EDEN PRAIRIE
Signature: /s/ Robert Golden, Attorney-in-Fact
Signature date: 26 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONMD transaction

Common Stock

Conversion of derivative security

Transaction value: $546,368
Shares: +479,270
Change %: +17%
Price: $1.14
Shares after: 3,242,465
Date: 17 Jun 2025
Ownership: Direct
Footnotes: F1

ONMD transaction

Common Stock

Conversion of derivative security

Transaction value: $1,298,078
Shares: +1,828,279
Change %: +56%
Price: $0.7100
Shares after: 5,070,744
Date: 19 Jun 2025
Ownership: Direct
Footnotes: F2

ONMD transaction

Common Stock

Purchase

Transaction value: $700,000
Shares: +1,666,666
Change %: +33%
Price: $0.4200
Shares after: 6,737,410
Date: 20 Jun 2025
Ownership: Direct
Footnotes: F3

ONMD transaction

Common Stock

Purchase

Transaction value: $12,705
Shares: +16,500
Change %: +0.24%
Price: $0.7700
Shares after: 6,753,910
Date: 19 Aug 2025
Ownership: Direct
Footnotes: F4

ONMD transaction

Common Stock

Purchase

Transaction value: $11,550
Shares: +15,000
Change %: +0.22%
Price: $0.7700
Shares after: 6,768,910
Date: 21 Aug 2025
Ownership: Direct

ONMD transaction

Common Stock

Purchase

Transaction value: $9,975
Shares: +13,300
Change %: +0.2%
Price: $0.7500
Shares after: 6,782,210
Date: 25 Aug 2025
Ownership: Direct
Footnotes: F5

ONMD transaction

Common Stock

Purchase

Transaction value: $119,612
Shares: +173,350
Change %: +2.6%
Price: $0.6900
Shares after: 6,955,560
Date: 26 Aug 2025
Ownership: Direct
Footnotes: F6

ONMD transaction

Common Stock

Purchase

Transaction value: $14,748
Shares: +21,374
Change %: +0.31%
Price: $0.6900
Shares after: 6,976,934
Date: 27 Aug 2025
Ownership: Direct
Footnotes: F7

ONMD transaction

Common Stock

Purchase

Transaction value: $13,600
Shares: +17,000
Change %: +0.24%
Price: $0.8000
Shares after: 6,993,934
Date: 28 Aug 2025
Ownership: Direct
Footnotes: F8

ONMD transaction

Common Stock

Purchase

Transaction value: $8,930
Shares: +10,890
Change %: +0.16%
Price: $0.8200
Shares after: 7,004,824
Date: 29 Aug 2025
Ownership: Direct
Footnotes: F9

ONMD transaction

Common Stock

Purchase

Transaction value: $20,671
Shares: +24,319
Change %: +0.35%
Price: $0.8500
Shares after: 7,029,143
Date: 02 Sep 2025
Ownership: Direct
Footnotes: F10

ONMD transaction

Common Stock

Purchase

Transaction value: $9,453
Shares: +11,670
Change %: +0.17%
Price: $0.8100
Shares after: 7,040,813
Date: 03 Sep 2025
Ownership: Direct
Footnotes: F11

ONMD transaction

Common Stock

Purchase

Transaction value: $10,275
Shares: +11,810
Change %: +0.17%
Price: $0.8700
Shares after: 7,052,623
Date: 04 Sep 2025
Ownership: Direct
Footnotes: F12

ONMD transaction

Common Stock

Purchase

Transaction value: $1,806
Shares: +2,100
Change %: +0.03%
Price: $0.8600
Shares after: 7,054,723
Date: 05 Sep 2025
Ownership: Direct
Footnotes: F13

ONMD transaction

Common Stock

Purchase

Transaction value: $637
Shares: +700
Change %: +0.01%
Price: $0.9100
Shares after: 7,055,423
Date: 18 Sep 2025
Ownership: Direct
Footnotes: F14

ONMD transaction

Common Stock

Purchase

Transaction value: $1,112
Shares: +1,250
Change %: +0.02%
Price: $0.8900
Shares after: 7,056,673
Date: 19 Sep 2025
Ownership: Direct
Footnotes: F15

ONMD transaction

Common Stock

Purchase

Transaction value: $380
Shares: +400
Change %: +0.01%
Price: $0.9500
Shares after: 7,057,073
Date: 22 Sep 2025
Ownership: Direct
Footnotes: F16

ONMD transaction

Common Stock

Purchase

Transaction value: $5,301
Shares: +5,700
Change %: +0.08%
Price: $0.9300
Shares after: 7,062,773
Date: 23 Sep 2025
Ownership: Direct
Footnotes: F17

ONMD transaction

Common Stock

Purchase

Transaction value: $17,544
Shares: +17,200
Change %: +0.24%
Price: $1.02
Shares after: 7,079,973
Date: 24 Sep 2025
Ownership: Direct
Footnotes: F18

ONMD transaction

Common Stock

Purchase

Transaction value: $1,288
Shares: +1,250
Change %: +0.02%
Price: $1.03
Shares after: 7,081,223
Date: 25 Sep 2025
Ownership: Direct
Footnotes: F19

ONMD transaction

Common Stock

Award

Transaction value: $0
Shares: +200,000
Change %: +2.8%
Price: $0.000000
Shares after: 7,281,223
Date: 24 Nov 2025
Ownership: Direct
Footnotes: F20

ONMD transaction

Common Stock

Award

Transaction value: $0
Shares: +45,000
Change %: +0.62%
Price: $0.000000
Shares after: 7,326,223
Date: 26 Nov 2025
Ownership: Direct
Footnotes: F21

ONMD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,311,970
Date: 17 Jun 2025
Ownership: By trust for children
Footnotes: F22

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ONMD transaction Derivative

Senior Secured Convertible Note

Conversion of derivative security

Transaction value: $546,368
Shares: -479,270
Change %: -100%
Price: $1.14
Shares after: 0
Date: 17 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 479,270
Exercise price: $1.14
Footnotes: F1, F8

ONMD transaction Derivative

Warrants (Right to Buy

Purchase

Transaction value: $178
Shares: +5,946
Change %
Price: $0.0300
Shares after: 5,946
Date: 09 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,946
Exercise price: $11.50

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 22 footnotes

Footnote F1

On June 28, 2023, Data Knights Acquisition Corp. ("Data Knights") (the predecessor of the issuer) and certain investors, including the reporting person (collectively, the "Purchasers"), entered into a securities purchase agreement pursuant to which Data Knights issued and sold to the Purchasers senior secured convertible notes (the "PIPE Notes"), which are convertible into shares of common stock at each Purchasers' election, at a conversion price equal to the lower of (i) $10.00 per share, or (ii) 92.5% of the lowest volume weighted average trading price for the ten (10) trading days immediately preceding the conversion date, subject to a floor price of $1.14. The PIPE Notes matured on the first anniversary of the issuance date (November 7, 2024), subject to extension pursuant to the terms of the PIPE Notes. The conversion shares included accrued interest from the date of issuance.

Footnote F2

On June 19, 2025, the issuer entered into an agreement with the reporting person to convert an aggregate of approximately $1.3 million of outstanding principal and accrued interest under certain shareholder loans and business combination extension loans.

Footnote F3

On June 20, 2025, the issuer entered into a subscription agreement with the reporting person, pursuant which the issuer agreed to sell 1,666,666 shares of common stock to the reporting person at a purchase price of $0.42 per share, totaling $700,000 in gross proceeds to the issuer.

Footnote F4

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.76 to $0.79, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in the footnotes of this report.

Footnote F5

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.74 to $0.75, inclusive.

Footnote F6

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.66 to $0.79, inclusive.

Footnote F7

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.68 to $0.72, inclusive.

Footnote F8

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.78 to $0.81, inclusive.

Footnote F9

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.79 to $0.85, inclusive.

Footnote F10

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.83 to $0.88, inclusive.

Footnote F11

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.77 to $0.86, inclusive.

Footnote F12

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.84 to $0.92, inclusive.

Footnote F13

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.84 to $0.90, inclusive.

Footnote F14

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.89 to $0.94, inclusive.

Footnote F15

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.88 to $0.92, inclusive.

Footnote F16

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.93 to $0.99, inclusive.

Footnote F17

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.91 to $0.96, inclusive.

Footnote F18

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.01 to $1.05, inclusive.

Footnote F19

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.03 to $1.04, inclusive.

Footnote F20

Represents restricted stock units ("RSUs") granted under the OneMedNet Corporation 2022 Equity Incentive Plan (the "2022 Plan") as employment compensation. RSUs vest as to one-third (1/3) of the RSUs on the first anniversary of the vesting start date of January 1, 2025, with the remaining RSUs vesting thereafter in equal quarterly installments on the last day of each fiscal quarter over the subsequent two (2) years, provided that the recipient remains in continuous service through each vesting date.

Footnote F21

Represents RSUs granted as director compensation under the 2022 Plan for board service in fiscal year 2025. The RSUs vest on December 31, 2025, subject to the reporting person's continued service with the issuer through the vesting date.

Footnote F22

The shares are held by trust with an independent trustee, in which the reporting person has no investment control. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 or for any other purpose.